Richard JD - Dentsply Sirona General Development
| XRAY Stock | USD 18.64 0.12 0.65% |
Executive
Richard JD is General Development of Dentsply Sirona
| Age | 57 |
| Address | 13320-B Ballantyne Corporate Place, Charlotte, NC, United States, 28277-3607 |
| Phone | 844 848 0137 |
| Web | https://www.dentsplysirona.com |
Dentsply Sirona Management Efficiency
The company has return on total asset (ROA) of 0.0232 % which means that it generated a profit of $0.0232 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1399) %, meaning that it created substantial loss on money invested by shareholders. Dentsply Sirona's management efficiency ratios could be used to measure how well Dentsply Sirona manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.04 in 2024. Return On Capital Employed is likely to rise to -0.01 in 2024. At this time, Dentsply Sirona's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 271.9 M in 2024, whereas Total Assets are likely to drop slightly above 3.7 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Saleem Cheeks | AngioDynamics | N/A | |
| Kerri DiPietro | Haemonetics | N/A | |
| Brandon Schnittker | Hologic | 40 | |
| Brian JD | Merit Medical Systems | 63 | |
| Dawn Haake | ResMed Inc | N/A | |
| David Pendarvis | ResMed Inc | 65 | |
| Juan Serna | AngioDynamics | N/A | |
| John JD | Hologic | 63 | |
| Rudy Poussot | West Pharmaceutical Services | N/A | |
| Peter Dunne | Hologic | 68 | |
| Scott Christensen | Hologic | N/A | |
| Greg Rodetis | Becton Dickinson and | N/A | |
| Laurie Miller | Haemonetics | 50 | |
| Erik Anderson | Hologic | 42 | |
| Michael Garrison | Becton Dickinson and | 54 | |
| Jim Ellis | ResMed Inc | N/A | |
| Michelle Fox | Teleflex Incorporated | N/A | |
| Alastair Robertson | ResMed Inc | N/A | |
| Todd Friedman | ResMed Inc | N/A | |
| Ricardo Alvarez | Merit Medical Systems | N/A | |
| Dr CFA | West Pharmaceutical Services | 57 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | 0.0232 |
Dentsply Sirona Leadership Team
Elected by the shareholders, the Dentsply Sirona's board of directors comprises two types of representatives: Dentsply Sirona inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dentsply. The board's role is to monitor Dentsply Sirona's management team and ensure that shareholders' interests are well served. Dentsply Sirona's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dentsply Sirona's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andreas Frank, Executive Officer | ||
| Dan Workinger, Treasurer | ||
| Simon Campion, President, CEO | ||
| Erania Brackett, SVP Sustainability | ||
| Richard Wagner, Chief Officer | ||
| Richard JD, General Development | ||
| Cheree Johnson, Chief VP | ||
| Dane Baumgardner, AttorneyInFact | ||
| Richard Rosenzweig, General Development | ||
| Lisa Yankie, VP Officer | ||
| Andrew Robinson, VP Officer | ||
| Emily Miner, Senior Officer | ||
| Gerard Campbell, Group RCO | ||
| Cord Staehler, VP CTO | ||
| Andrea Daley, Vice Relations | ||
| Kevin Boyle, Senior Officer | ||
| Andrea Frohning, Senior Officer | ||
| Kevin Czerney, Vice Officer | ||
| Glenn Coleman, Executive CFO | ||
| Robert Johnson, Senior Sustainability | ||
| Bruce Peatey, Group RCO |
Dentsply Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dentsply Sirona a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | 0.0232 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 5.71 B | ||||
| Shares Outstanding | 198.78 M | ||||
| Shares Owned By Insiders | 0.40 % | ||||
| Shares Owned By Institutions | 99.60 % | ||||
| Number Of Shares Shorted | 13.77 M | ||||
| Price To Earning | 19.16 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dentsply Stock Analysis
When running Dentsply Sirona's price analysis, check to measure Dentsply Sirona's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dentsply Sirona is operating at the current time. Most of Dentsply Sirona's value examination focuses on studying past and present price action to predict the probability of Dentsply Sirona's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dentsply Sirona's price. Additionally, you may evaluate how the addition of Dentsply Sirona to your portfolios can decrease your overall portfolio volatility.